Spelling suggestions: "subject:"estrogen receptor"" "subject:"östrogen receptor""
51 |
The Preparation of Aryl-Carboranes and Re-Metallocarboranes as Anti-EstrogensChankalal, Raymond 02 1900 (has links)
<p> The estrogen receptor (ER) plays an integral role in the proliferation of hormone dependent breast cancer. Recently a number of organometallic compounds and closocarboranes, which demonstrate affinity for the estrogen receptor, were prepared as novel types of anti-estrogens. This thesis describes the synthesis and characterization of a new class ofinorganic anti-estrogens derived from Re-metallocarboranes. </p> <p> Chapter 2 describes the first series of targets which include three monoarylated Re-metallocarboranes. Two different synthetic routes were used to complex the [Re(C0)3t core to carborane ligands, one of which involves microwave irradiation of a one pot mixture that produces the desired complexes in almost complete conversion ratios. One compound, 2.10, contains a single phenol substituents, which is predicted to show ER binding affinity based on previous reports ofthe closo-carborane analogue. </p> <p> Chapter 3 describes the synthesis and characterization of diarylated Remetallocarboranes. Two of the compounds, 3.7 and 3.8, are expected to show high binding affinity for the ER because they are inorganic analogues of the well known antiestrogen Tamoxifen. </p> / Thesis / Master of Science (MSc)
|
52 |
Investigating the Balance Between Estrogen Receptor Mediated Cell Proliferation and Genomic SurveillanceBrown, Margarita 07 November 2016 (has links) (PDF)
Breast cancer is a leading cause of cancer in women and the second leading cause of cancer death. Lifetime exposure to estrogen contributes to this risk but high dose estrogen has been used to induce apoptosis as treatment for breast cancer. These opposing tumorigenic and anti-tumorigenic effects of estrogen may be regulated differently by the two Estrogen Receptors (ER), Estrogen Receptor alpha (ERα) and Estrogen Receptor beta (ERβ). Although the receptors share a 96% homology in their DNA binding domain, they are unique in the ligand-binding domain with 53% amino acid homology. Previous studies have shown that ERα drives cell proliferation in the mammary gland. We propose that ERβ mediates genomic surveillance in the mammary gland to restrict proliferation. To test this hypothesis we first characterized each of our reference breast cancer cell lines to determine the ERα and ERβstatus. We found that ERβ transcript and protein are expressed in some breast cancer cell lines that are considered to be “triple-negative” (HCC1937 and MDA MB 231). Using specific ER agonists, we were able to demonstrate that amphiregulin, a secreted protein and a marker of ERα activation, is upregulated by ERα agonists in a dose dependent manner in cell lines that have ERα (T47D & MCF7). ERα agonists do not enhance AREG expression in cell lines that primarily expresses ERβ (HCC1937). Instead, CEBPd, a tumor suppressor, is expressed at high levels in this cell line. In conclusion, targeting ERβ has the potential to selectively activate tumor suppressor pathways without stimulating proliferation and may provide a treatment option for patients for whom inhibition of ERa is not an option.
|
53 |
Cellular localization of the estrogen receptor GPER1 in colorectal cancer cell lines / Cellulär lokalisering av östrogenreceptorn GPER1 i kolorektalcancercellerLundvall, Malin January 2022 (has links)
Colorectal cancer is the third most common cancer type in the world with a mortality rate of around 2000 people in Sweden, year 2018. Women tend to have a lower risk of developing and progressing colorectal cancer, specifically premenopausal women. This indicates that Estrogen plays an important role in protecting from colorectal cancer. Estrogen has been shown to both inhibit colon cancer cell proliferation and stimulate cell apoptosis through several pathways. Estrogen signaling mediates through the estrogen receptors (ER) ERα, ERβ and GPER1. ERβ has been linked to suppression of colorectal cancer tumors but is downregulated in colon cancer tissue. The trans-membrane receptor GPER1 has also been found present in colorectal cells, however its effect on the CRC progression is still debated. It has been shown to both contribute to cell proliferation and the downregulation of cell proliferation, depending on the cell conditions. The location of the GPER1 receptor plays an important role to understand the signaling pathways and how the receptor could be a potential therapeutic target for cancer treatment. The localization of the receptor affects all types of molecular interactions with the protein and decides the cellular environment of the signaling protein. The location of GPER1 is still debatable and the localization has not been confirmed with a validated primary antibody. Anti-GPR30 703480 and three anti-FLAG (F7425, F1804, 14793) primary antibodies were used for detection on HT29, HCT116 and SiHa cells. Immunofluorescence (IF) followed by visualization with a confocal fluorescence microscope was used to localize the receptor tagged with a FLAG (Flag-GPER1). Western Blot (WB) and qPCR were used to validate the primary antibodies. The results obtained with the antibody anti-GPR30 show a signal mainly limited to the cytoplasm of the cells. However, the negative control SiHa presented a similar fluorescent signal while a low expression of GPER1 in WB and qPCR were measured, which indicates that the signal detected with the anti-GPR30 is not specific in IF. The anti-FLAG antibodies did not give sufficient signal detection for the FLAG protein on the different cellular populations. Further tests with different antibody dilutions for anti-GPR30 are required and new anti-Flag antibodies should be tested for IF detection. / Kolorektalcancer är den tredje vanligaste cancertypen i världen och hade år 2020 en dödlighet på omkring 2000 personer i Sverige. Risken att drabbas och utveckla kolorektalcancer är lägre för kvinnor, specifikt för kvinnor före klimakteriet. Detta indikerar att hormonet östrogen har en betydande roll vid utveckling av kolorektalcancer. Östrogen har kopplats till hämmande av cellspridning samt stimulering av celldöd vid koloncancer. Östrogen förmedlas via östrogenreceptorerna ERα, ERβ och GPER1. ERβ har kopplats till hämmande av kolorektalcancertumörer, men receptorns uttryck har samtidigt studerats minska då cancertumörerna ökar. Östrogenreceptorn GPER1 uttrycks även i kolorektalcancervävnad, men forskare har tidigare haft en delad syn på receptorns påverkan på cancerns utveckling då ett högt uttryck av receptorn både bidragit till ökad cellväxt och nedreglering av celltillväxt, beroende på cellens tillstånd. GPER1 receptorns cellulära placering har en viktig påverkan på receptorns signalvägar och är viktig för att förstå hur receptorn kan vara ett potentiellt terapeutiskt mål för cancerbehandling. Placeringen av receptorn påverkar alla molekylara interaktioner med proteinet och påverkar den cellulära miljön hos proteinet. Receptorns placering är ännu inte klarlagd och lokaliseringen har ännu inte studerats med en validerad antikropp. Immunfluorescens (IF) användes för att lokalisera receptorn. Western Blot (WB) och qPCR användas för att validera de primära antikropparna som användes vid IF. Anti- GPR30 703 480 och tre anti-FLAG (F7425, F1804, 14793) antikroppar användes för att studera cellinjerna HT29 och HCT116. Resultatet var att receptorn huvudsakligen är placerad omkring cellkärnan med en majoritet i cytoplasman när antikroppen anti-GPR30 användes. Samtidigt detekterades receptorn i den negativa cellinjen SiHa vilket kan indikera att receptorn inte är specifik för GPER1 vid användning av IF. Cellinjen SiHa innehåller en låg mängd av proteinet GPER1. Ytterligare studier krävs för att validera antikroppen. Framtida projekt kan använda en lägre koncentrationen på den primära antikroppen samt att använda en ny detergent för att minska eventuella ospecifika bindningar. Samtliga anti-FLAG antikroppar ansågs ej lämpliga vid IF användning. Samtidigt krävs det ytterligare studier för att fastställa detta. IF resultatet från mage, lunga och levervävnaderna vid användning av anti-GPER1 indikerar att antikroppen binder in specifikt till vävnaderna. Skillnaden mellan IF resultatet från vävnader och celler kan bero på olika fixeringsmetoder.
|
54 |
Physiologie et physiopathologie des effets membranaires du récepteur des œstrogènes alpha (ERα) dans la glande mammaire / Physiology et physiopathology of membrane estrogen receptor alpha (ERα) in mammary glandGagnac, Laurine 05 March 2018 (has links)
It is well established that the 17-estradiol is involved in the development and homeostasis of reproductive and extra-reproductive tissues, particularly the mammary gland. Estradiol classically binds to Estrogen Receptor (ERα), which is a member of the nuclear receptor superfamily. ER mediates nuclear (transcription) and plasma membrane (signaling) ERα function. Interestingly, the membrane initiated steroid signaling (MISS) required a post translational modification of the receptor: palmitoylation of the human Cys-447 or the murine Cys-451 counterpart. The main objectives of my PhD thesis were to decipher the physiological role of membrane ERα in mammary gland development and to understand how the membrane ER signaling impact breast cancer. To do so, we used the transgenic mouse model C451A-ER in which the single point mutation (C451A) was introduced to abolish palmitoylation of ER (membrane addressing signal). We demonstrate that the point mutation of the palmitoylation site of ER alters the paracrine signaling of luminal epithelial cells and by consequence the repopulation properties of the mammary stem cells. We also studied the involvement of the membrane effects of the Estrogen Receptor ERα in the 17β-estradiol response dose of the mammary gland. Finally, by breeding the C451A-ER mice with the widely used transgenic mice model of tumorigenesis (PyMT), we provide the first evidence that the membrane ERα influences tumorigenesis. These findings pave the way on an unexpected role of non-genomic function of ERα in the mammary gland physiology and physiopathology. / It is well established that the 17-estradiol is involved in the development and homeostasis of reproductive and extra-reproductive tissues, particularly the mammary gland. Estradiol classically binds to Estrogen Receptor (ERα), which is a member of the nuclear receptor superfamily. ER mediates nuclear (transcription) and plasma membrane (signaling) ERα function. Interestingly, the membrane initiated steroid signaling (MISS) required a post translational modification of the receptor: palmitoylation of the human Cys-447 or the murine Cys-451 counterpart. The main objectives of my PhD thesis were to decipher the physiological role of membrane ERα in mammary gland development and to understand how the membrane ER signaling impact breast cancer. To do so, we used the transgenic mouse model C451A-ER in which the single point mutation (C451A) was introduced to abolish palmitoylation of ER (membrane addressing signal). We demonstrate that the point mutation of the palmitoylation site of ER alters the paracrine signaling of luminal epithelial cells and by consequence the repopulation properties of the mammary stem cells. We also studied the involvement of the membrane effects of the Estrogen Receptor ERα in the 17β-estradiol response dose of the mammary gland. Finally, by breeding the C451A-ER mice with the widely used transgenic mice model of tumorigenesis (PyMT), we provide the first evidence that the membrane ERα influences tumorigenesis. These findings pave the way on an unexpected role of non-genomic function of ERα in the mammary gland physiology and physiopathology.
|
55 |
Παρακολούθηση με συνδυασμό κολπικού υπερηχογραφήματος και απόξεσης ενδομήτριου γυναικών με καρκίνο του μαστού υπό αγωγή με ταμοξιφαίνη – σε συνδυασμό με μελέτη των πολυμορφισμών των γονιδίων της μεταβολικής οδού των οιστρογόνωνΦωτόπουλος, Ανδρέας 16 December 2008 (has links)
Στις μετεμμηνοπαυσιακές γυναίκες με καρκίνο μαστού, θετικό για οιστρογονικούς υποδοχείς, μετά από χειρουργική θεραπεία, η μακροχρόνια χορήγηση της ταμοξιφαίνης (SERM πρώτης γενεάς), έχει αποδειχθεί ευεργετική. Ο σκοπός της παρούσης μελέτης, ήταν να διαπιστώσει, εάν οι πολυμορφισμοί του γονιδίου των ER (PvuII & XbaI του ERα και οι RsaI & AluI του Erβ), οι οποίοι έχουν συσχετισθεί με καρκίνο μαστού, σχετίζονται με το στάδιο του καρκίνου του μαστού ή την ανταπόκριση του ενδομητρίου στην μακροχρόνια αγωγή με ταμοξιφαίνη, στις μετεμμηνοπαυσιακές γυναίκες με καρκίνο του μαστού.
Η μελέτη περιέλαβε 87 μετεμμηνοπαυσιακές γυναίκες με καρκίνο μαστού θετικό για οιστρογονικούς υποδοχείς, στις οποίες χορηγήθηκε ταμοξιφαίνη. Η μέση ηλικία των ασθενών ήταν 58,7± 4,7 έτη, και η μέση διάρκεια της αγωγής με ταμοξιφαίνη ήταν 3,9 ± 1,1 έτη. Το γονιδιακό DNA απομονώθηκε από τα λευκά αιμοσφαίρια δειγμάτων περιφερικού αίματος με την κλασσική μέθοδο φαινόλης - χλωροφορμίου. Τα κλάσματα των γονιδίων των ERα και Erβ, τα οποία συμπεριελάμβαναν τις θέσεις των πολυμορφισμών, πολλαπλασιάσθηκαν με την αλυσιδωτή αντίδραση πολυμεράσης (PCR). Ο προσδιορισμός της παρουσίας των πολυμορφισμών στο DNA πραγματοποιήθηκε με την χρήση ενζύμων περιορισμού. Συμπερασματικά, στις Ελληνίδες μετεμμηνοπαυσιακές γυναίκες με καρκίνο του μαστού υπό αγωγή με ταμοξιφαίνη, οι πολυμορφισμοί των οιστρογονικών υποδοχέων, δεν συνδέθηκαν, ούτε με την παρουσία παθολογίας του ενδομητρίου, ούτε με το στάδιο του καρκίνου του μαστού. / In postmenopausal women with estrogen receptor (ER) positive breast cancer, after surgical treatment long term tamoxifen administration has been proved beneficial.
The aim of the present study was to identify whether these ER gene polymorphisms are associated with breast cancer stage or endometrial responsiveness to long-term tamoxifen treatment in postmenopausal women with breast cancer. The study included 87 postmenopausal women with estrogen receptor positive breast cancer treated with tamoxifen. The mean age of patients was 58,7 ± 4,7 years and the mean duration of Tamoxifen treatment was 3.9 ± 1,1 years. Genomic DNA was extracted from peripheral blood leukocyte samples by the standard phenol/chloroform procedure. Fragments of the ERα and ERβ genes encompassing the polymorphic sites were amplified by the polymerase chain reaction (PCR). The determination of presence of polymorphisms in the DNA was realised with restriction endonucleases. Ιn conclusion, in Greek postmenopausal women with breast cancer under tamoxifen treatment, Estrogen Receptors polymorphisms were not linked to either the presence of endometrial pathology or the stage of breast cancer.
|
56 |
Selective estrogen receptor modulators, nitric oxide and vascular reactivity. / CUHK electronic theses & dissertations collectionJanuary 2004 (has links)
Wong Chi Ming. / "August 2004." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (p. 182-215). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.
|
57 |
Estudo sobre o tamoxifeno : papel dos receptores de estrogênio na resposta terapêutica e efeitos cognitivos do tratamentoLichtenfels, Martina January 2016 (has links)
Introdução: Estimativas mostram que mais de dois terços das mulheres com câncer de mama possuem receptores hormonais positivos, e recebem terapia endócrina como tratamento, sendo tamoxifeno (TAM) o tratamento padrão (EBCTCG 2005; Davies et al., 2012). Porém, muitas pacientes se tornam resistentes com o passar do tempo. Estudos prévios mostraram que a expressão do receptor de estrogênio β (REβ) aumenta a resposta ao tratamento com TAM em células de câncer de mama, assim como a coexpressão de REα e REβ esta associada com maior ação proliferativa de TAM (Treeck et al., 2010; Sun et al., 2014). Também foi observada a existência de “cross-talk” entre os RE e a família do receptor do fator de crescimento epidérmico (HER) na resposta ao tratamento com TAM (Lindberg et al., 2011; Blows et al., 2010). Objetivo: Verificar a expressão do REβ, e suas interações com REα e receptores HER, durante o tratamento com TAM e em células resistentes ao TAM. Métodos: A expressão do REβ foi analisada em dois bancos de dados contendo informações de pacientes com câncer de mama. A expressão de RNAm dos RE, receptores HER e vias de sinalização PTEN, Akt e MAPK foram avaliadas após tratamento com TAM, em células resistentes ao TAM e em células silenciadas para os genes dos RE. Também foi avaliada a viabilidade celular após tratamento com TAM e nas células silenciadas para os genes dos RE. Resultados: Pacientes com câncer de mama apresentaram expressão reduzida do REβ, e os subtipos de câncer de mama REα positivos apresentaram baixa expressão do REβ quando comparados aos subtipos REα negativos. Células expressando níveis moderados de REβ apresentaram melhor resposta ao tratamento com TAM. Diminuição nos níveis dos RE é acompanhada por aumento nos níveis dos receptores ErbB2 e ErbB3, aumento de PTEN e diminuição de Akt e MAPK3 após tratamento com TAM. ERβ modula a ação antiproliferativa do TAM através da via de MAPK3. Células resistentes ao TAM apresentaram baixos níveis dos RE e altos níveis dos receptores EGFR, ErbB3 e ErbB4. Conclusão: Estes resultados demonstram que o REβ, e suas interações com REα e receptores HER, possuem papel importante na resposta ao tratamento com TAM. / Introduction: Approximately two-thirds of all breast cancer patients overexpress hormonal receptors, and are treated with endocrine therapy, being tamoxifen (TAM) the standard treatment. However many of initial responders to TAM as first-line experience relapse. Several mechanisms have been proposed to explain the occurrence of acquired TAM resistance. Previous studies showed that estrogen receptor β (ERβ) expression is associated with better response to tamoxifen treatment, as the co-expression of ERα and ERβ is associated with TAM antiproliferative effects. Moreover, there is growing interest about the cross-talk between ERs and ErbB family in response to endocrine therapy. Suggesting that TAM can acts through ERβ and/or ErbB family as compensatory pathways. Objective: To evaluate the expression of ERβ and the relation of ERβ with ERα and ErbB family in response to TAM treatment and in TAM resistant cells. Methods: ERβ expression was analyzed in two different databases of breast cancer patients. The mRNA levels of ER, HER receptors and PTEN, Akt and MAPK signal pathways were measured after TAM treatment, in TAM resistance cells and in cells silenced for ER genes. The cellular viability was also measured after TAM treatment, in TAM resistance cells and in cells silenced for ER genes. Results: Breast cancer patients presented reduced ERβ expression and the ERα-positive breast cancer subtypes presented lower ERβ levels when compared to ERα-negative breast cancer subtypes. Cells expressing moderates levels of ERβ presented better response to TAM treatment. Down-regulation of ERs induced by TAM treatment are accompanied with an increase in ErbB2 and ErbB3, reduced AKT and MAPK3 mRNA levels and increased PTEN levels. ERβ modulates TAM anti-proliferative effects through MAPK3 pathway. TAM– resistant cells expressed decreased ER mRNA levels and increased EGFR, ErbB3 and ErbB4 levels. Demonstrating that the cross-talk between ERs and HER family influence the response to TAM treatment. Conclusion: These results provide additional data indicating the importance of ERβ, and the relation with ERα and HER receptors, to predict TAM responsiveness.
|
58 |
Impact of estradiol, estrogen receptor subtype-selective agonists and genistein on energy homeostasis / Einfluss von Estradiol, Estrogenrezeptor-Subtyp-selektiven Agonisten und Genistein auf die EnergiehomöostaseWeigt, Carmen 25 November 2013 (has links) (PDF)
The prevalence of obesity is dramatically increasing and thus constitutes a major risk factor for developing chronic diseases such as type 2 diabetes, dyslipidemia, cardiovascular diseases, and certain forms of cancer. High-caloric nutrition and a lack of physical activity are the main contributing factors for this global epidemic. Estrogen receptors (ERs) are recognized to be involved in many processes related to the control of energy homeostasis.
In my studies, I investigated the impact of estrogens (17beta-estradiol (E2)) on energy homeostasis. Special emphasis was given to the effects of two synthetic ER subtype-selective agonists, 16alpha-LE2 (Alpha) and 8beta-VE2 (Beta), to determine to what extend the two distinct ER subtypes are involved in the underlying molecular mechanisms. Because of its estrogenic activity and also its widespread use as a nutritional supplement the influence of the isoflavone genistein (Gen) was examined. For this purpose two different female rat models were used: Wistar rats with nutrition-induced obesity and leptin resistant Zucker diabetic fatty (ZDF) rats. In both experiments, the animals were ovariectomized (OVX) and treated with vehicle (untreated controls) or the estrogenic compounds.
The most important finding was that treatment of OVX animals with Beta enlarges soleus muscle fiber sizes in both animal models compared to untreated OVX animals. This anabolic effect may in turn improve the muscle/fat ratio of the body that enhances muscular uptake and utilization of fuels. By contrast, in the gastrocnemius muscle of OVX ZDF rats substitution with Alpha increased expression and distribution of the insulin-dependent glucose transporter 4 (GLUT4). Consequently, systemic insulin sensitivity in both animal models was improved by treatment with estrogenic compounds compared to untreated OVX animals. The strongest effect was observed in E2-treated rats that indicate an additive effect through activation of both pathways.
In all OVX rats, treatment with either ER subtype-selective agonist showed an anti-lipogenic effect in adipose tissue, liver, and skeletal muscle of nutrition-induced obese Wistar rats in comparison to OVX animals without treatment. Decreased visceral fat mass, adipocyte sizes, serum leptin levels, triglyceride accumulation in liver and muscle as well as mRNA expression of genes that are involved in lipo-/adipogenesis reflected this. Therefore, the lower visceral fat mass as well as decreased accumulation of triglycerides in non-adipose tissues such as liver and skeletal muscle most likely contributes to the improved insulin sensitivity in such treated animals.
Gen exerted effects similar to those of the ER beta-selective agonist (except on adipose tissue in Wistar rats). Especially, the similar ability to induce anabolic activity in the soleus muscle might be highly relevant. Gen-treated animals might have a more effective utilization of fuels compared to untreated OVX animals because they showed a lower TG content in muscle and liver as well as improved glucose metabolism.
In conclusion, because of my studies and the fact that ER beta signaling is not involved in proliferation of uterus and mammary gland, an effective way to treat obesity and co-morbidities in postmenopausal women might be substances that only activate ER beta. A combination with physical activity may support the therapy of obesity and co-morbidities. The isoflavone Gen is able to activate both ER-subtypes. This compound is already placed on the market for treatment of postmenopausal complaints, although adverse effects of Gen cannot be excluded so far (e.g., increased risk of breast cancer). However, Gen might be a natural alternative – not only to the conventional hormone replacement therapy, but also as a strategy for treatment of obesity and co-morbidities – that deserves further research with respect to these new data. / Die dramatisch zunehmende Prävalenz der Adipositas und das damit verbundene Risiko für Folgeerkrankungen wie Diabetes mellitus, Hypertonie, Dyslipidämie und koronare Herzkrankheiten stellt eine große Herausforderung für das Gesundheitswesen dar. Als Hauptursache wird ein chronisches Missverhältnis der Energiehomöostase aufgrund permanenter Überernährung und Bewegungsmangel postuliert. Estrogene beeinflussen den Glukose- und Lipidstoffwechsel und sind somit in die Regulation des Energiehaushaltes involviert. Estrogene vermitteln ihre Effekte über zwei Estrogenrezeptor (ER)-Subtypen, den ER alpha und den ER beta.
Ziel der vorliegenden Arbeit war es mittels tierexperimentellen Studien den Einfluss von Estrogenen, speziell 17beta-Estradiol, auf den Energiehaushalt zu untersuchen. Um einen tieferen Einblick in die zugrundeliegenden molekularen Mechanismen zu erhalten, wurden zwei Subtyp-selektive ER-Agonisten, 16alpha-LE2 (Alpha) and 8beta-VE2 (Beta), synthetischer Herkunft eingesetzt. Aufgrund der estrogenen Aktivität und der Verfügbarkeit als Nahrungsergänzungsmittel wurde des Weiteren der Einfluss des Isoflavons Genistein untersucht. Für die Studien wurden zwei Tiermodelle genutzt: zum einen weibliche Wistar-Ratten mit ernährungsinduzierter Adipositas und zum anderen weibliche leptinresistente „Zucker diabetic fatty“ (ZDF)-Ratten. Die Tiere wurden ovarektomiert (OVX) und entweder mit einem Vehikel (unbehandelte Kontrolltiere) oder mit der entsprechenden estrogenen Substanz behandelt.
Die interessanteste Erkenntnis war, dass im Vergleich zu unbehandelten OVX-Tieren beider Tiermodelle die Behandlung mit Beta zur Vergrößerung der Faserquerschnitte im Soleusmuskel führte. Dieser anabole Effekt könnte die muskuläre Aufnahme und Verwertung von Brennstoffmolekülen verbessern und sich insgesamt positiv auf die Körperzusammensetzung auswirken. Den stärksten Effekt hinsichtlich einer erhöhten Expression und Translokation des insulinabhängigen Glukosetransporters 4 (GLUT4) in die Zellmembran des Gastrocnemiusmuskels zeigte sich dagegen durch die Behandlung von OVX ZDF-Ratten mit Alpha. Im Endergebnis zeigten die Tiere beider Modelle durch die Behandlung mit estrogenen Substanzen eine verbesserte systemische Insulinsensitivität im Vergleich zu unbehandelten Kontrolltieren. E2-behandelte Tiere tolerierten die Glukose am besten und lassen einen additiven Effekt aufgrund der Aktivierung beider Signalwege vermuten.
Im Vergleich zu unbehandelten OVX Wistar-Ratten führte die Behandlung mit E2 oder mit jeweils einem der beiden ER-Subtyp-selektiven Agonisten zu einer geringeren viszeralen Fettmasse, kleineren Fettzellen, niedrigeren Leptinspiegeln im Serum und geringeren Triglyzeridwerten in Leber und Muskel. Auf der Ebene der Genexpression waren zudem geringere mRNA-Spiegel von lipo- und adipogenen Genen messbar. Somit scheinen beide ER-Subtypen in die antilipogene Wirkung von E2 involviert zu sein. Sowohl die reduzierte viszerale Fettmasse als auch die geringere Anreicherung von Triglyzeriden in Leber und Muskel tragen sehr wahrscheinlich ebenfalls zur verbesserten Insulinsensitivität bei.
Die Behandlung von OVX Tieren mit Gen führte zu ähnlichen Ergebnissen wie die Behandlung mit Beta. Eine alleinige Ausnahme stellte das Fettgewebe dar, da hier eine Gen-Behandlung keine antilipogenen/-adipogenen Effekte zeigte. Speziell die Fähigkeit von Gen ebenfalls anabol zu wirken, könnte die molekulare Grundlage sein, weshalb Gen-behandelte Tiere im Vergleich zu unbehandelten Tiere eine verbesserte Toleranz gegenüber Glukose und eine geringere Anreicherung von Triglyzeriden in Muskel und Leber zeigten.
Der ER beta ist nicht in die estrogenvermittelte Proliferation von Uterus und Brustdrüse involviert. Vor diesem Hintergrund lassen meine Ergebnisse vermuten, dass eine Behandlung mit ER beta-selektiven Substanzen eine effektive Möglichkeit darstellt, um Adipositas und deren Folgeerkrankungen in postmenopausalen Frauen zu behandeln, ohne deren Risiko für estrogenabhängige Krebsformen zu erhöhen. Eine Kombination mit regelmäßiger körperlicher Aktivität könnte die Erfolge bei der Behandlung von Adipositas und deren Folgeerkrankungen noch maximieren bzw. eine geringere Dosierung der verwendeten Substanz bei gleichbleibendem Behandlungserfolg ermöglichen. Das Isoflavon Gen mit seiner Fähigkeit beide ERs zu aktivieren ist eine bereits auf dem Markt befindliche Substanz und wird zur Behandlung von postmenopausalen Beschwerden eingesetzt, obwohl mögliche negative Effekte (z.B. ein erhöhtes Brustkrebsrisiko) noch nicht abschließend geklärt sind. Falls diese Risiken von Gen ausgeräumt werden können, könnte diese Substanz eventuell eine kostengünstige Alternative darstellen, um sowohl postmenopausale Beschwerden als auch Adipositas und deren Folgekrankheiten zu behandeln.
|
59 |
Food, friends and foes: estrogens and social behaviour in mice.Clipperton Allen, Amy Elizabeth 13 January 2012 (has links)
This thesis investigates estrogens' modulation of three aspects of social cognition (aggression and agonistic behaviour, social learning, and social recognition). Sex-typical agonistic behaviour (males: overt attacks, females: more subtle dominance behaviours) was increased in gonadectomized mice by estrogen receptor alpha (ERα) agonist 1,3,5-tris(4-hydroxyphenyl)-4-propyl-1H-pyrazole (PPT), while non-overt agonistic behaviour was increased in male and female gonadally intact mice by ERβ agonist 7-Bromo-2-(4-hydroxyphenyl)-1,3-benzoxazol-5-ol (WAY-200070). Estrogens also affected the social transmission of food preferences (STFP). Acute estrogen and ERβ agonists WAY-200070 and 2,3-bis(4-hydroxyphenyl)propionitrile (DPN) prolonged the preference for the demonstrated food when administered pre-acquisition, likely by affecting motivation or the nature of the social interaction, while acute PPT blocked the STFP. All mice receiving any of the three treatments chronically showed a prolonged demonstrated food preference, suggesting a loss of ER specificity. Individual differences in social recognition may relate to increased oxytocin (OT) and vasopressin (AVP) mRNA, and ERα and ERβ gene activation, in the medial preoptic area, and decreased mRNA for ERs, OT receptor (OTR), AVP and AVP receptors 1a and 1b in the lateral amygdala. Additionally, dorsolateral septum ERs, progesterone receptor, and OTR may relate to social interest without affecting social recognition. Our and others' results suggest that estrogens, OT and AVP are all involved in social behaviours and mediate social recognition, social learning, social interactions, and aggression. ERs differently modulate the two types of social learning investigated here: ERα is critical for social recognition, but impairs social learning, while ERβ is less important in social recognition, and prolongs the demonstrated food preference in the STFP. This may be due to differences in receptor brain distributions or in downstream neurochemical systems that mediate these behaviours. The results of this thesis suggest that estrogens, through the various systems they modulate, have a key role to play in social behaviour. Further investigations of how estrogens effect change in these systems at the molecular and cellular level, as well as the critical brain areas and downstream effectors involved in these complex behaviours, are needed, and could contribute to therapeutic interventions in socially-based, sexually dimorphic disorders, like the autism spectrum disorders, and women receiving hormone replacement therapy for negative peri- or post-menopausal symptoms. / National Science and Engineering Research Council (PGS-D, CGS-M)
|
60 |
Estrogen recepter [a] and STAT5b crosstalk : implications for estrogen-stimulated breast cancer proliferation /Fox, Emily Marie. January 2008 (has links)
Thesis (Ph. D.)--University of Virginia, 2008. / [a] in title is the Greek letter alpha. Includes bibliographical references. Also available online through Digital Dissertations.
|
Page generated in 0.0769 seconds